

# The future is here.

Development and commercialization of a novel personalized regenerative medicine platform for a variety of medical indications



10+ years of research at  
Tel Aviv University, Israel



\$12M in academic  
research grants



Numerous publications  
in leading journals



Patents pending &  
extensive knowhow



## Autologous matrix and cells derived from patients tissue

- Patient-specific extracellular matrix-based thermo-responsive hydrogel + cells
- Easily manufactured from patients tissue
- A platform enabling engineering of functional mature tissues for a variety of medical conditions
- Implants are fully autologous and do not induce an immune response

No alternate technology is currently available for producing completely autologous tissue implants where both the cells and the matrix are generated from the patient himself and therefore will not be rejected after transplantation

## Promising pre-clinical studies:

1. Acute and chronic Spinal Cord Injury (SCI)
2. Myocardial Infarction (MI)
3. Age related Macular Degeneration (AMD)
4. Parkinson's Disease

## The disease burden

- Approximately 17,000 new cases of acute SCI per year in the US
- Usually irreversible loss of motor, sensory and autonomic functions
- Estimated cost of care post SCI is US\$ 350K-1M for the first-year alone
- Net present value of the life cost for a quadriplegic patient injured at the age of 25 is estimated at US\$ 4.8M


## Pathophysiology

- Acute Spinal Cord Injury
- Hemorrhage and spinal cord swelling
- Reduced blood flow that leads to ischemic necrosis
- Cavity development and white matter reduction
- Chronic Spinal Cord Injury

## First in human clinical trial (2024)

- Phase I/IIa clinical trial of autologous spinal cord neural implant for the treatment of paralysis due to traumatic Spinal Cord Injury (SCI)
- 5-10 patients\*
- Multicenter study in Israel

*\*Subject to regulatory approval*



## Other products in the pipeline

- Autologous cardiac patch for myocardial infarction
- Autologous dopaminergic implants for Parkinson's disease
- Autologous implants for Age-related Macular Degeneration (AMD)
- 3D bioprinting

## The Team



Asaf Toker, MD  
**CEO**



Tal Dvir, PhD  
**CSO**



Yossi Dagan  
**CFO**



Alon Sinai  
**COO**



Doron Birger  
**Chairman of the Board**



Tal Ben Neriah  
**Director of Operations**



Tamar Harel Adar, PhD  
**VP R&D**



Dr. Nicholas Theodore, M.D.  
**Scientific Advisory Board**



Eckhard von Keutz  
**Scientific Advisory Board**